These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32451413)

  • 21. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis-associated colon cancer.
    Ohnishi T; Hashizume C; Taniguchi M; Furumoto H; Han J; Gao R; Kinami S; Kosaka T; Okazaki T
    FASEB J; 2017 Sep; 31(9):3816-3830. PubMed ID: 28522594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and characterization of selective human sphingomyelin synthase 2 inhibitors.
    Adachi R; Ogawa K; Matsumoto SI; Satou T; Tanaka Y; Sakamoto J; Nakahata T; Okamoto R; Kamaura M; Kawamoto T
    Eur J Med Chem; 2017 Aug; 136():283-293. PubMed ID: 28505533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deficiency of sphingomyelin synthase 2 prolongs survival by the inhibition of lymphoma infiltration through ICAM-1 reduction.
    Taniguchi M; Ueda Y; Matsushita M; Nagaya S; Hashizume C; Arai K; Kabayama K; Fukase K; Watanabe K; Wardhani LO; Hayashi K; Okazaki T
    FASEB J; 2020 Mar; 34(3):3838-3854. PubMed ID: 31970839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sphingomyelin synthase 2 deficiency decreases atherosclerosis and inhibits inflammation in mice].
    Qin R; Chen ML; Zhu K; Deng JB; Shi YY
    Sheng Li Xue Bao; 2010 Aug; 62(4):333-8. PubMed ID: 20717634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. M2 polarization of macrophages by Oncostatin M in hypoxic tumor microenvironment is mediated by mTORC2 and promotes tumor growth and metastasis.
    Shrivastava R; Asif M; Singh V; Dubey P; Ahmad Malik S; Lone MU; Tewari BN; Baghel KS; Pal S; Nagar GK; Chattopadhyay N; Bhadauria S
    Cytokine; 2019 Jun; 118():130-143. PubMed ID: 29625858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deficiency of sphingomyelin synthase 1 but not sphingomyelin synthase 2 reduces bone formation due to impaired osteoblast differentiation.
    Matsumoto G; Hashizume C; Watanabe K; Taniguchi M; Okazaki T
    Mol Med; 2019 Dec; 25(1):56. PubMed ID: 31847800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sphingomyelin Synthase 2 Inhibition Ameliorates Cerebral Ischemic Reperfusion Injury Through Reducing the Recruitment of Toll-Like Receptor 4 to Lipid Rafts.
    Xue J; Yu Y; Zhang X; Zhang C; Zhao Y; Liu B; Zhang L; Wang L; Chen R; Gao X; Jiao P; Song G; Jiang XC; Qin S
    J Am Heart Assoc; 2019 Nov; 8(22):e012885. PubMed ID: 31718447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
    Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
    Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer.
    Charan M; Das S; Mishra S; Chatterjee N; Varikuti S; Kaul K; Misri S; Ahirwar DK; Satoskar AR; Ganju RK
    Cell Death Dis; 2020 Sep; 11(9):774. PubMed ID: 32943608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sphingomyelin synthase activity affects TRIF-dependent signaling of Toll-like receptor 4 in cells stimulated with lipopolysaccharide.
    Prymas K; Świątkowska A; Traczyk G; Ziemlińska E; Dziewulska A; Ciesielska A; Kwiatkowska K
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Feb; 1865(2):158549. PubMed ID: 31678513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti-PD-1 immunotherapy.
    Zhang D; Wang M; Wang W; Ma S; Yu W; Ren X; Sun Q
    J Leukoc Biol; 2024 Sep; 116(3):579-588. PubMed ID: 38478709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
    Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
    Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.
    Staquicini FI; Hajitou A; Driessen WH; Proneth B; Cardó-Vila M; Staquicini DI; Markosian C; Hoh M; Cortez M; Hooda-Nehra A; Jaloudi M; Silva IT; Buttura J; Nunes DN; Dias-Neto E; Eckhardt B; Ruiz-Ramírez J; Dogra P; Wang Z; Cristini V; Trepel M; Anderson R; Sidman RL; Gelovani JG; Cristofanilli M; Hortobagyi GN; Bhujwalla ZM; Burley SK; Arap W; Pasqualini R
    Elife; 2021 Jun; 10():. PubMed ID: 34060472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. All members in the sphingomyelin synthase gene family have ceramide phosphoethanolamine synthase activity.
    Ding T; Kabir I; Li Y; Lou C; Yazdanyar A; Xu J; Dong J; Zhou H; Park T; Boutjdir M; Li Z; Jiang XC
    J Lipid Res; 2015 Mar; 56(3):537-545. PubMed ID: 25605874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.
    Edwards DN; Ngwa VM; Raybuck AL; Wang S; Hwang Y; Kim LC; Cho SH; Paik Y; Wang Q; Zhang S; Manning HC; Rathmell JC; Cook RS; Boothby MR; Chen J
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33320840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chamaejasmenin B, an Inhibitor for Metastatic Outgrowth, Reversed M2-Dominant Macrophage Polarization in Breast Tumor Microenvironment.
    Li Q; Sun L; Liu L; Ran Q; Du X; Yang Q; Wang Y; Li Y; Chen Y; Weng X; Cai W; Zhu X
    Front Immunol; 2021; 12():774230. PubMed ID: 35027915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization.
    Yang R; Xie Y; Li Q; Ye Y; Shi Y; Zhao X; Wu C; Xu Y; Wang R; Zhang Y; Yang X; Han X; Liu S
    Biomed Pharmacother; 2021 Sep; 141():111883. PubMed ID: 34246955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.
    Li Z; Hailemariam TK; Zhou H; Li Y; Duckworth DC; Peake DA; Zhang Y; Kuo MS; Cao G; Jiang XC
    Biochim Biophys Acta; 2007 Sep; 1771(9):1186-94. PubMed ID: 17616479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.